DAFTAR PUSTAKA

1. Kapita Selekta Kedokteran Edisi 3 Jilid 2. FKUI: Media Aesculapius.

2. Purwanto I. Purpura Trombositopenia imun. Dalam: Sudoyo AW,

Setiyohadi B, Alwi I, Simadibrata MK, Setiati S, eds. Buku Ajar Ilmu
Penyakit Dalam 5th ed. Jakarta:Pusat Penerbitan Departemen Ilmu Penyakit
Dalam FKUI; 2010.

3. Lambert MP, Gernsheimer TB. Clinical updates in adult immune

thrombocytopenia. Blood 25. 2017; volume 129 (21)

4. Guyton, A. C., Hall, J. E. Buku Ajar Fisiologi Kedokteran. Edisi 12. Jakarta

: EGC. 2014.

5. Bensouda LG, Nordon c, Michel M, Viallard JF, Adoue D, Bertrand NM, et

al. Immune thrombocytopenia in adults: A prospective cohort study of

clinical features and predictors of outcome. Haematologica. 2016: Vol 10

(9): 1039-1045.

6. Lee JY, Lee JH, Lee H, Kang B, Kim JW, Kim SH, et al. Epidemiology and

management of primary immune thrombocytopenia: a nationwide

population-based study in Korea. Thrombosis Research. 2017.

7. Golshan A, Abrishami F, Sohrabi T. A study of epidemiology and

therapeutic response of patients with immune thrombocytopenic purpura.

Iran J Ped Hematol Oncol. 2016; Vol 6 (2): p. 115-123.

8. Longo DL. Harrison’s Hematology and Oncology. New York: The

McGraw-Hill Companies, Inc.; 2010

55
9. Mehta AB, Hoffbrand AV. Gangguan hemostasis: dinding pembuluh darah

dan trombosit. 2nd ed. Jakarta: Erlangga;2006. p.73-5.

10. Sekhon S, Roy V. Thrombocytopenia in adults: a practical approach to

evaluation and management. South Med J. 2006;99(5):491-8.

11. Khodadi E, Asnafi AA, Shahrabi S, Shahjahani M, Saki N. Bone marrow

niche in immune thrombocytopenia: a focus on megakaryopoiesis. Ann

Hematol. 2016;95(11):1765-1776.

12. Cines DB, Cuker A, Semple JW. Pathogenesis of immune

thrombocytopenia. Presse Med. 2014; 43(4 Pt 2):e49-e59

13. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among

adult patients with primary immune thrombocytopenia in the United

Kingdom General Practice Research Database. Haematologica. 2010;95(7):

1167-1175

14. Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous

thromboembolism in patients with primary chronic immune

thrombocytopenia: a Danish population-based cohort study. Br J Haematol.

2011;152(3):360-362.

15. Qiu J, Liu X, Li X, et al. CD8(1) T cells induce platelet clearance in the

liver via platelet desialylation in immune thrombocytopenia. Sci Rep.

2016;6:27445.

16. Baeten DL, Kuchroo VK. How cytokine networks fuel inflammation:

interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013;19(7):

824-825.

56
17. Rocha AM, Souza C, Rocha GA, et al. The levels of IL-17A and of the

cytokines involved in Th17 cell commitment are increased in patients with

chronic immune thrombocytopenia. Haematologica. 2011;96(10):1560-

1564.

18. Malara A, Abbonante V, Di Buduo CA, Tozzi L, Currao M, Balduini A.

The secret life of a megakaryocyte: emerging roles in bone marrow

homeostasis control. Cell Mol Life Sci. 2015; 72(8):1517-1536.

19. Hoffmeister KM, Falet H. Platelet clearance by the hepatic Ashwell-Morrell

receptor: mechanisms and biological significance. Thromb Res. 2016;

141(suppl 2):S68-S72.

20. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA;

American Society of Hematology. The American Society of Hematology

2011 evidence-based practice guideline for immune thrombocytopenia.

Blood. 2011;117(16):4190-4207.

21. Melboucy-Belkhir S, Khellaf M, Augier A, et al. Risk factors associated

with intracranial hemorrhage in adults with immune thrombocytopenia: a

study of 27 cases. Am J Hematol. 2016;91(12):E499-E501.

22. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults

and children with primary immune thrombocytopenia: a systematic review.

J Thromb Haemost. 2015;13(3): 457-464

23. Grimaldi-Bensouda L, Nordon C, Michel M, et al; Group for the PGRx-ITP

Study. Immune thrombocytopenia in adults: a prospective cohort study of

57
 clinical features and predictors of outcome. Haematologica. 2016;101(9):

1039-1045.

24. Arnold DM, Clare R, Jaffer AM, Aubie B, Li N, Kelton JG. Misdiagnosis of

primary immune thrombocytopenia and frequency of bleeding: lessons from

the Mc master ITP registry. Blood Advances. 2017; Vol 1 (25): p. 2414-20

25. Provan D, Stasi R, Newland AC, et al. International consensus report on the

investigation and management of primary immune thrombocytopenia.

Blood. 2010;115(2): 168-186.

26. Li HQ, Zhang L, Zhao H, Ji LX, Yang RC. Chronic idiopathic

thrombocytopenic purpura in adult Chinese patients: a retrospective single-

centered analysis of 1791 cases. Chin Med J (Engl). 2005; 118(1):34-37.

27. Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood. 2017; Vol

130 (21).

28. Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective

11-year analysis of obstetric patients with idiopathic thrombocytopenic

purpura. Blood. 2003;102(13): 4306-4311.

29. Loustau V, Debouverie O, Canoui-Poitrine F, et al. Effect of pregnancy on

the course of immune thrombocytopenia: a retrospective study of 118

pregnancies in 82 women. Br J Haematol. 2014; 166(6):929-935.

30. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and

dexamethasone vs dexamethasone monotherapy in newly diagnosed patients

with primary immune thrombocytopenia. Blood. 2013;121(11): 1976-1981.

58
31. Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A

novel triple therapy for ITP using high-dose dexamethasone, low-dose

rituximab, and cyclosporine (TT4). Blood. 2015; 126(4):500-503.

32. Newland A, Godeau B, Priego V, et al. Remission and platelet responses

with romiplostim in primary immune thrombocytopenia: final results from a

phase 2 study. Br J Haematol. 2016;172(2): 262-273.

33. Ahmed R, Devasia AJ, Viswabandya A, et al. Long-term outcome following

splenectomy for chronic and persistent immune thrombocytopenia (ITP) in

adults and children: splenectomy in ITP. Ann Hematol. 2016;95(9):1429-

1434.

34. Guan Y, Wang S, Xue F, et al. Long-term results of splenectomy in adult

chronic immune thrombocytopenia. Eur J Haematol. 2017;98(3): 235-241.

35. Provan D, Newland AC. Current management of primary immune

thrombocytopenia. Adv Ther. 2015;32(10):875-887.

36. Gonz ´alez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of

eltrombopag after romiplostim in primary immune thrombocytopenia. Br J

Haematol. 2015;169(1):111-116.

37. Saleh MN, Bussel JB, Cheng G, et al; EXTEND Study Group. Safety and

efficacy of eltrombopag for treatment of chronic immune thrombocytopenia:

results of the long-term, open-label EXTEND study. Blood. 2013;121(3):

537-545.

38. Saputra BA, Rodiani, Puspita RD. Kehamilan dengan Trombositopenia.

Medula. 2018; Vol 8 (1): p 94-101.

59
39. Gernsheimer T, James AH, Stasi R. How i treat thrombocytopenia in

pregnancy. Blood. 2013;122(1):38-47.

40. Marks PW. Obstetric Hemorrhage. In: Colman RW, Marder VJ, Clowes

AW, George JN, Goldhaber SZ. Hemostasis and Thrombosis: Basic

Principles and Clinical Practice. Edisi ke-5. Philadelphia: Lippincott

Williams & Wilkins; 2006

41. Wyszynski DF, Carman WJ, Cantor AB, et al. Pregnancy and birth

outcomes among women with idiopathic thrombocytopenic purpura. J

Pregnancy. 2016;2016:8297407

42. Siddal J. Guideline for the management of Thrombocytopenia in pregnancy.

Maternity Guidlines. 2015. 2017;GL927:1- 8.

60